1. The emerging role of MET/HGF inhibitors in oncology;Scagliotti;Cancer Treat Rev,2013
2. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib;Roy;Anticancer Agents Med Chem,2015
3. The treatment landscape in thyroid cancer: a focus on cabozantinib;Weitzman;Cancer Manag Res,2015
4. Exelixis announces U.S. FDA deems New Drug Application sufficiently complete and grants priority review for cabozantinib as a treatment for advanced renal cell carcinoma. Business Wire https://www.businesswire.com/news/home/20160128005475/en/Exelixis-Announces-U.S.-FDA-Deems-New-Drug
5. Cabozantinib for the treatment of metastatic medullary thyroid carcinoma;Nix;J Adv Pract Oncol,2014